LX 101 - Innostellar Biotherapeutics
Alternative Names: LX-101 - Innostellar BiotherapeuticsLatest Information Update: 26 Feb 2024
At a glance
- Originator Innostellar Biotherapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Retinal dystrophies
Most Recent Events
- 12 Sep 2023 Innostellar Biotherapeutics initiates the phase I/II trial in Retinal dystrophies (In adolescents, In children, In adults, In the elderly) in China (Subretinal) (NCT06212297)
- 02 Jul 2022 Phase-I/II clinical trials in Retinal dystrophies (In adolescents, In children, In adults, In the elderly) in China (Subretinal) (NCT06196827)